Elite Pharmaceuticals INC /NV/

Elite Pharmaceuticals announces the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in multiple strengths.

Elite Pharmaceuticals announced a significant increase in consolidated revenues and income from operations for the fiscal year ended March 31, 2026, driven by new product launches and existing product growth.

Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for a generic anticonvulsant drug, moving closer to an FDA Abbreviated New Drug Application.

Elite Pharmaceuticals announced the submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic anticoagulant product.

Elite Pharmaceuticals, Inc. announced it will host a conference call on February 18, 2026, to discuss its third-quarter fiscal year 2026 financial results.

Elite Pharmaceuticals, Inc. reported a significant 92% increase in consolidated revenues to $36.3 million for the second quarter of fiscal year 2026, driven by strong sales of lisdexamfetamine products.

Elite Pharmaceuticals announced a significant increase in revenue and net income for the six months ended September 30, 2025, driven by manufacturing fees and new product launches, alongside recent FDA approvals.

Elite Pharmaceuticals, Inc. reported a 114% surge in total revenue to $40.2 million for Q1 2025, driven by strong Elite label product sales and new launches, though a net loss of $5.9 million was recorded primarily due to a non-cash warrant valuation adjustment.

Elite Pharmaceuticals saw a revenue increase but also a larger net loss in the third quarter of fiscal year 2025, ended December 31, 2024.

Elite Pharmaceuticals saw a significant increase in revenue driven by its Elite-branded products, but also experienced a larger net loss due to changes in the fair value of derivative instruments and increased operating expenses.

Elite Pharmaceuticals saw a significant increase in revenue during the first quarter of fiscal year 2025, driven by strong sales of its Elite-branded products.

Elite Pharmaceuticals saw a significant increase in revenue during the third quarter of fiscal year 2024, driven by the launch of its own-label products.

Elite Pharmaceuticals Inc. announced a significant increase in revenue for the fiscal year ended March 31, 2026, driven by new product launches and expanded sales.

Elite Pharmaceuticals, Inc. announced a 48% increase in total revenue to $84.0 million for the fiscal year ended March 31, 2025, primarily due to four new product launches and increased sales from its Elite Label product line, though the company reported a net loss of $4.3 million and identified material weaknesses in internal controls.

Elite Pharmaceuticals, Inc. reports a significant 66% increase in revenue for fiscal year 2024, driven by the launch of its own label products.

Elite Pharmaceuticals' EVP of Operations, Douglas Plassche, exercised 2.5 million stock options at $0.03 per share, increasing his direct beneficial ownership to 6 million shares.

Elite Pharmaceuticals EVP Operations, Douglas Plassche, sold 800,000 shares of common stock at $0.624 per share.

Elite Pharmaceuticals' EVP Operations, Doug Plassche, reported selling 500,000 shares and exercising 2.5 million stock options, increasing direct common stock ownership.

Elite Pharmaceuticals' Chief Commercial Officer, Kirko Kirkov, has acquired 16,366 shares of common stock, indicating a vote of confidence in the company's future.

Elite Pharmaceuticals' Executive Vice President of Operations, Douglas Plassche, reported the sale of 200,000 stock options at $0.579 per share, with a transaction date listed as July 8, 2025.

Douglas Plassche, Executive Vice President of Operations at Elite Pharmaceuticals Inc., exercised 2.5 million stock options at $0.03 per share, increasing his direct beneficial ownership of common stock.